1 Douillard JY, Siena S, Cassidy J, et al. Randomized, phase Ⅲ trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study[J]. J Clin Oncol, 2010, 28(31): 4697-4705.
[2]
2 Peeters M, Price TJ, Cervantes A, et al. Randomized phase Ⅲ study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2010, 28(31): 4706-4713.
[3]
3 Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase Ⅲ trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy[J]. J Clin Oncol, 2010, 28(23): 3687-3694.
[4]
4 Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase Ⅲ MAX Study[J]. J Clin Oncol, 2010, 28(19): 3191-3198.
[5]
5 Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase Ⅲ study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(6): 918-927.
9 Chen J, Peng H, Ou-Yang X, et al. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells[J]. Melanoma Res, 2008, 18(5): 322-329.
[10]
10 Lee SY, Kim GT, Roh SH, et al. Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines[J]. Biosci Biotechnol Biochem, 2009,73(4): 811-816.
[11]
11 Wang CZ, Xie JT, Fishbein A, et al. Antiproliferative effects of different plant parts of Panax notoginseng on SW480 human colorectal cancer cells[J]. Phytother Res, 2009, 23(1): 6-13.
[12]
12 Li B, Zhao J, Wang CZ, et al. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53[J]. Cancer Lett, 2011, 301(2): 185-192.
[13]
13 Liu TG, Huang Y, Cui DD, et al. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice[J]. BMC Cancer, 2009, 9: 250.
[14]
14 Xu TM, Xin Y, Cui MH, et al. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer[J]. Chin Med J, 2007, 120(7): 584-588.
[15]
15 Kim SM, Lee SY, Yuk DY, et al. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel[J]. Arch Pharm Res, 2009, 32(5): 755-765.
